Population-based laboratory surveillance of Hafnia alvei isolates in a large Canadian health region

Annals of Clinical Microbiology and Antimicrobials

Volumn 5, Issue , 2006, Pages

  Laupland, Kevin B ^a   Church, Deirdre L ^a,b   Ross, Terry ^a   Pitout, Johann D D ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b CALGARY LABORATORY SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFALOTIN; CEFAZOLIN; CEFPODOXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM;

ACCURACY; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CANADA; COMMUNITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HAFNIA ALVEI; HEALTH SURVEY; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION RISK; LABORATORY; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; SEX RATIO; SOFT TISSUE INFECTION; URINARY TRACT INFECTION; AGE; ENTEROBACTERIACEAE INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; RISK FACTOR;

AGE DISTRIBUTION; AGE FACTORS; AGED; ALBERTA; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HAFNIA ALVEI; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 33746781675     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-5-12     Document Type: Article

References (16)

1. Janda JM, Abbott SL: The genus Hafnia: from soup to nuts. Clin Microbiol Rev 2006, 19:12-18.
2. Gunthard H, Pennekamp A: Clinical significance of extraintestinal Hafnia alvei isolates from 61 patients and review of the literature. Clin Infect Dis 1996, 22:1040-1045.
3. Rodriguez-Guardado A, Boga JA, Diego ID, Ordas J, Alvarez ME, Perez F: Clinical characteristics of nosocomial and community-acquired extraintestinal infections caused by Hafnia alvei. Scand J Infect Dis 2005, 37:870-872.
4. Fazal BA, Justman JE, Turett GS, Telzak EE: Community-acquired Hafnia alvei infection. Clin Infect Dis 1997, 24:527-528.
5. Ramos A, Damaso D: Extraintestinal infection due to Hafnia alvei. Eur J Clin Microbiol Infect Dis 2000, 19:708-710.
6. Washington JA, Birk RJ, Ritts REJ: Bacteriologic and epidemiologic characteristics of Enterobacter hafniae and Enterobacter liquefaciens. J Infect Dis 1971, 124:379-386.
7. Schuchat A, Hilger T, Zell E, Farley MM, Reingold A, Harrison L, Lefkowitz L, Danila R, Stefonek K, Barrett N, Morse D, Pinner R: Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis 2001, 7:92-99.
8. Statistics Canada. Available at: http://www12.statcan.ca/english/ profil01/PlaceSearchForm1.cfm Accessed January 6, 2005.
9. Laupland KB, Church DL, Mucenski M, Sutherland LR, Davies HD: Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003, 187:1452-1459.
10. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
11. Pastor P, Medley F, Murphy TV: Invasive pneumococcal disease in Dallas County, Texas: results from population-based surveillance in 1995. Clin Infect Dis 1998, 26:590-595.
12. Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S: Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 2005, 56:532-537.
13. Laupland KB: Population-based epidemiology of intensive care: critical importance of ascertainment of residency status. Crit Care 2004, 8:R431-6.
14. Stock I, Rahman M, Sherwood KJ, Wiedemann B: Natural antimicrobial susceptibility patterns and biochemical identification of Escherichia albertii and Hafnia alvei strains. Diagn Microbiol Infect Dis 2005, 51:151-163.
15. Nadjar D, Rouveau M, Verdet C, Donay L, Herrmann J, Lagrange PH, Philippon A, Arlet G: Outbreak of Klebsiella pneumoniae producing transferable AmpC-type beta-lactamase (ACC-1) originating from Hafnia alvei. FEMS Microbiol Lett 2000, 187:35-40.
16. Girlich D, Naas T, Bellais S, Poirel L, Karim A, Nordmann P: Heterogeneity of AmpC cephalosporinases of Hafnia alvei clinical isolates expressing inducible or constitutive ceftazidime resistance phenotypes. Antimicrob Agents Chemother 2000, 44:3220-3223.